The Orgenesis JV agreement was on 5-6-19. Using April, May, and June, you see a lot of restricted shares issued to third parties for consulting services. No one could tell by this if it was anything related to Orgenesis.
On April 2, 2019, the Company issued a total of 300,000 restricted shares to a third party for consulting services already provided, valued at $180,000 based upon the market price of the shares of $0.60 on the date of issuance.
On May 23, 2019, the Company issued 150,000 fully vested common shares to a third party for consulting services for a 12 month term, in accordance with the terms of a consulting agreement dated April 17, 2019. The shares were valued at $63,000 based upon the market price of the shares of $0.42 on the date of issuance, and will be amortized over the life of the agreement. An additional 100,000 shares were issued on June 7, 2019, valued at $24,000, based upon the market price of the shares of $0.24 on the date of issuance. An additional 200,000 shares were issued on August 19, 2019, valued at $34,000, based upon the market price of the shares of $0.17 on the date of issuance. The additional shares issued are being amortized over the remaining term of the agreement.
On June 6, 2019, the Company entered into a consulting agreement to issue 500,000 restricted shares to two parties, for consulting services to be provided over the year term of the consulting agreement, valued at $115,000 based upon the market price of the shares of $0.23 on the date of the agreement. The fair value of the shares was recognized in Prepaid assets and the expense will be recognized over the term of the agreement. The shares were issued on July 2, 2019, and are included in Stock payable as of June 30, 2019.
